Tang Wei, Shi Qing-Ping, Ding Feng, Yu Mei-Ling, Hua Jian, Wang Yong-Xin
Int J Clin Pharmacol Ther. 2017 Apr;55(4):304-321. doi: 10.5414/CP202833.
To analyze the correlation between gene polymorphisms and warfarin maintenance dosage, as well as the correlation of dosage of warfarin with age and ethnicity.
We retrieved related studies published between January 2000 and March 2016 from PubMed, Embase, the Cochrane Library, Web of Science, VIP, CNKI, and Wan Fang data. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data and crosscheck data. Then, RevMan5.3 software was used to perform a meta-analysis.
53 studies were included in the meta-analysis. The most prevalent genotypes were -1639 AA, 1173 TT, and 3730 GG in both Asian and Caucasians, but the distribution frequencies of all three were higher in Asians than in Caucasians. The meta-analysis showed that compared with homozygous -1639 AA carriers, carriers of type GA, GG, and G (GA + GG) required 45% (95% confidence interval (CI) 42 - 49), 77% (95% CI 70 - 84), and 51% (95% CI 47 - 55) higher warfarin doses, respectively. Carriers of type CC, TC, and C (CC + TC) required 83% (95% CI 73 - 92), 26% (95% CI 23 - 29), and 53% (95% CI 44 - 62) higher warfarin doses, respectively, compared to homozygous 1173 TT carriers. Carriers of type AA, GA, and A (AA + GA) required 40% (95% CI 29 - 51), 25% (95% CI 17 - 33), and 33% (95% CI 21 - 45) higher warfarin doses, respectively, compared to carriers of the homozygous 3730 GG polymorphism (all p < 0.05). Subgroup analysis showed that Asian patients aged ≤ 60 years carrying 1173 CC, TC, and C genotypes required 28%, 39%, and 22% higher warfarin doses, respectively, compared with patients aged > 60 years. Caucasian patients aged > 60 years carrying -1639 GA, GG and G genotypes needed 24%, 39%, and 37% lower warfarin doses, respectively, compared with patients aged ≤ 60 years. These differences were statistically significant (p < 0.05).
CONCLUSIONS: Our study showed that the relationship between
分析基因多态性与华法林维持剂量之间的相关性,以及华法林剂量与年龄和种族的相关性。
我们从PubMed、Embase、Cochrane图书馆、Web of Science、维普、中国知网和万方数据中检索了2000年1月至2016年3月发表的相关研究。两名评价员根据纳入和排除标准独立筛选文献,提取数据并交叉核对数据。然后,使用RevMan5.3软件进行荟萃分析。
荟萃分析纳入了53项研究。在亚洲人和白种人中,最常见的基因型分别为-1639 AA、1173 TT和3730 GG,但这三种基因型在亚洲人中的分布频率均高于白种人。荟萃分析表明,与纯合-1639 AA携带者相比,GA型、GG型和G型(GA + GG)携带者所需的华法林剂量分别高45%(95%置信区间(CI)42 - 49)、77%(95% CI 70 - 84)和51%(95% CI 47 - 55)。与纯合1173 TT携带者相比,CC型、TC型和C型(CC + TC)携带者所需的华法林剂量分别高83%(95% CI 73 - 92)、26%(95% CI 23 - 29)和53%(95% CI 44 - 62)。与纯合3730 GG多态性携带者相比,AA型、GA型和A型(AA + GA)携带者所需的华法林剂量分别高40%(95% CI 29 - 51)、25%(95% CI 17 - 33)和33%(95% CI 21 - 45)(所有p < 0.05)。亚组分析表明,年龄≤6岁且携带1173 CC、TC和C基因型的亚洲患者,与年龄>60岁的患者相比,所需的华法林剂量分别高28%、39%和22%。年龄>60岁且携带-1639 GA、GG和G基因型的白种人患者,与年龄≤60岁的患者相比,所需的华法林剂量分别低24%、39%和37%。这些差异具有统计学意义(p < 0.05)。
我们的研究表明,不同个体中